Clinical Trial Search

Primary: Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate — 3.13; 2.03; 4.66; 3.36 umol/min/L plasma — p=0.85

Primary: Median Cumulative Morphine Equivalent — 0; 2.5; 0; 5 Morphine Equivalents

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs). — 49; 5; 9; 0 Participants

Primary: Percentage of Participants With >=3 Diagnostic Rating Using Radlex Scale — 92.63 percentage of participants

Primary: Change in Physical Activity From Baseline to 12 Weeks — 8.82; 2.32 minutes per day

Primary: Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin's Lymphoma. — 79 cGy

Primary: Wolf Motor Function Test (WMFT) — 45.17; 49.75; 59.83; 49.80 units on a scale

Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm

Primary: Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment. — 57.6; 41.3 percentage of change from baseline (cm2)

Primary: Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity — 97; 5 Participants

Primary: Speech Perception in Quiet (Monosyllables) in Patients Implanted With Vibrant Soundbridge — 94.12 percentage of words correct

Primary: Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 — -0.33; 2.96; 3.47; 4.97 percent change

Primary: Changes in Attention Deficit Hyperactivity Disorder (ADHD) Symptoms - Adolescent Report — -4.27; -0.55 units on a scale — p=<.0001

Primary: Progression-free Survival Rate at 18 Months — 88.5; 96 percentage of participants

Primary: Compare the Overall Survival (OS) of Patients Treated With AEZS-108 to the OS of Patients Treated With Doxorubicin. — 196; 188; 60; 67 participants — p=0.5441